Carcinogenesis, Vol. 21, No. 4, 811-816,
April 2000
© 2000 Oxford University Press
Short Communications |
Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin
1 Center for Cancer Causation and Prevention, AMC Cancer Research Center, Denver, CO 80214,
2 Department of Dermatology, Case Western Reserve University, Cleveland, OH 44106 and
3 University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, CO 80262, USA
In this communication, we investigate the preventive effect of a flavonoid antioxidant, silymarin, on free radical-generating skin tumor promoting agent benzoyl peroxide (BPO)-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Topical application of silymarin at a dose of 6 mg prior to BPO resulted in a highly significant protection against BPO-induced tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated SENCAR mouse skin. The preventive effect of silymarin was evident in terms of a 70% reduction (P < 0.001) in tumor incidence, a 67% reduction (P < 0.001) in tumor multiplicity and a 44% decrease (P < 0.001) in tumor volume/tumor. In oxidative stress studies, topical application of BPO resulted in 75, 87 and 61% depletion in superoxide dismutase (SOD), catalase and glutathione peroxidase (GPX) activities in mouse epidermis, respectively. These decreases in antioxidant enzyme activities were significantly (P < 0.005–0.001) reversed by pre-application of silymarin in a dose-dependent manner. The observed effects of silymarin were 18–66, 32–72 and 20–67% protection against BPO-induced depletion of SOD, catalase and GPX activity in mouse epidermis, respectively. Silymarin pre-treatment also resulted in a dose-dependent inhibition (35–87%, P < 0.05–0.001) of BPO-induced lipid peroxidation in mouse epidermis. In inflammatory response studies, silymarin showed a strong inhibition of BPO-induced skin edema (62–85% inhibition, P < 0.001), myeloperoxidase activity (42–100% inhibition, P < 0.001) and interleukin-1
protein level in epidermis (36–81% inhibition, P < 0.001). These results, together with our other recent studies, suggest that silymarin could be useful in preventing a wide range of carcinogen and tumor promoter-induced cancers.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Deep and R. Agarwal Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Provinciali, F. Papalini, F. Orlando, S. Pierpaoli, A. Donnini, P. Morazzoni, A. Riva, and A. Smorlesi Effect of the Silybin-Phosphatidylcholine Complex (IdB 1016) on the Development of Mammary Tumors in HER-2/neu Transgenic Mice Cancer Res., March 1, 2007; 67(5): 2022 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hoh, D. Boocock, T. Marczylo, R. Singh, D. P. Berry, A. R. Dennison, D. Hemingway, A. Miller, K. West, S. Euden, et al. Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences. Clin. Cancer Res., May 1, 2006; 12(9): 2944 - 2950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsuda, K. Ferreri, I. Todorov, Y. Kuroda, C. V. Smith, F. Kandeel, and Y. Mullen Silymarin Protects Pancreatic {beta}-Cells against Cytokine-Mediated Toxicity: Implication of c-Jun NH2-Terminal Kinase and Janus Kinase/Signal Transducer and Activator of Transcription Pathways Endocrinology, January 1, 2005; 146(1): 175 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nyska, A. Suttie, S. Bakshi, L. Lomnitski, S. Grossman, M. Bergman, V. Ben-Shaul, P. Crocket, J. K. Haseman, G. Moser, et al. Slowing Tumorigenic Progression in TRAMP Mice and Prostatic Carcinoma Cell Lines Using Natural Anti-Oxidant from Spinach, NAO--A Comparative Study of Three Anti-Oxidants Toxicol Pathol, January 1, 2003; 31(1): 39 - 51. [Abstract] [PDF]
|
|